News Contact Us

Skyhawk and Takeda to sign agreement for neurodegenerative disease

Author : Pankaj Singh | Published Date : 2019-05-08 

The deal will mark the fourth industry collaboration for Massachusetts-based company Waltham. Earlier, Skyhawk had signed a partnership with Celgene worth $60 million.

RNA biotech Skyhawk Therapeutics will reportedly sign another R&D deal with Takeda Pharmaceutical company for allowing pharmaceutical company to use platform of biotech to create small molecules which will fix mis-splicing of RNA in neurodegenerative disease.

Reportedly, under the agreement, SkySTAR technology will be used by Skyhawk to detect and build molecules for “certain neurological disease targets” by preclinical stage. After the preclinical stage, Takeda will take over clinical development and commercialization.

Takeda has picked up the global rights to create and commercialize drugs against numerous targets, while Skyhawk gets the customary upfront fee and potential milestones and royalties down the line. Both the companies are yet to disclose the figures.

The deal will mark the fourth industry collaboration for Massachusetts-based company Waltham. Earlier, Skyhawk had signed a partnership with Celgene worth $60 million. Under the deal, the BigBiotech could license up to 5 new drug candidates. At that time, Skyhawk also had raised $40 million in common stock’s new funding round. The biotech had anticipated that $100 million would boost its first cancer drug to the clinic, separately from the partnership with Celgene, in the year 2019.

The Celgene deal was signed after $74 million agreement finalized in January with Biogen focused on developing medicines for spinal muscular atrophy, multiple sclerosis and other neurological diseases. Skyhawk has partners such as Cold Spring Harbor Laboratory, Lakepharma, MIT and ETH Zurich, and the Swiss Federal Institute of Technology.

Skyhawk’s SkySTAR (Small molecule Therapeutics for Alternative splicing of RNA) tech has been created to target RNA’s specific blinding pocket regions. These sites could be taken off during vital steps in the RNA splicing procedure, causing mis-splicing. The company anticipates that rearranging this skipping can treat the basic causes of numerous diseases.

For the record, Takeda Pharmaceutical Company Ltd is the Asia’s leading pharma company. The company is focused on gastroenterology, metabolic disorders, inflammation, neurology, and oncology.


Source Credit:  https://www.fiercebiotech.com/biotech/takeda-taps-skyhawk-s-rna-targeting-tech-for-neurodegenerative-disease

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Revival in UK hotel bookings after COVID-19 downturn, says Premier Inn

Published Date: 2020-07-09         Author: Pankaj Singh

UK has registered a revival in hotel bookings for conventional regional tourist destinations as people have started planning summer trips to the seaside and countryside, stated Premier Inn owner. The Chief Executive of Whitbread, Alison Brittain, has stated that larger cities like London continue... Read More

Fujitsu gravitates toward 'new normal' with new office working style

Published Date: 2020-07-08         Author: Pankaj Singh

Fujitsu Limited, a Japanese multinational IT company headquartered in Tokyo, has reportedly announced that it will boost its shift to becoming a digital transformation organization with an ambitious plan to transform the working style for its employees in Japan in the light of COVID-19 pandemic. ... Read More

Britain nears USD 625 million COVID-19 vaccine deals with Sanofi/GSK

Published Date: 2020-07-06         Author: Pankaj Singh

With over 100 vaccines are being tested and developed to stop the spread of COVID-19, it seems that governments worldwide are racing to secure supplies of vaccines even before their efficiency is proven. As per the latest news, Britain government is close to a USD 625 million supply deals with Sanof... Read More

© 2020 Fractovia. All Rights Reserved